Tag:

Moderna Therapeutics

Latest Headlines

Latest Headlines

Show me the money: Which drugs made the top 10 list on upfront deals?

Given the eyebrow-raising cash component in Celgene's new deal with Nogra, we thought it would be fun to list the top 10 upfronts paid for experimental drugs, ranked simply according to the cash included in the upfront--no surer sign of what a company really thinks about the potential of an experimental therapy or portfolio.

For its next trick, Moderna splits in two with $20M cancer venture

Moderna Therapeutics has chosen the big stage of the J.P. Morgan conference to unveil its next gambit: splitting in two and launching a standalone company to advance its oncology programs.

Cash-laden Moderna snags $125M in Alexion RNA deal

Cambridge, MA's Moderna Therapeutics is marching on with another high-dollar deal, getting $125 million up front to lend its messenger RNA platform to rare disease luminary Alexion Pharmaceuticals.

Moderna nails $110M to get mRNA tech into the clinic

Moderna Therapeutics is having quite a year, and the Cambridge, MA, biotech just put a $110 million capstone on 2013, raising a colossal new round and riding high on technology that promises to transform the human body into a drug factory.

Moderna lands $25M grant to develop its RNA platform against infectious diseases, bioterror

Moderna Therapeutics' messenger RNA therapy platform is attracting attention these days. The Cambridge, MA-based company has won a notable deal with the U.S. government--worth up to $25 million--to develop its therapeutics to make antibody-producing drugs that would combat emerging infectious diseases and biological health threats.

The 2013 Fierce 15 biotech execs take a bow

Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report

FierceBiotech's 2013 Fierce 15

Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...

Siemens CEO Peter Löscher ousted amid revenue struggle

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups

Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>

Biotech legend Termeer joins the board at Moderna

The biotech, which struck a major development deal with AstraZeneca just months after it shed stealth status, has landed former Genzyme CEO Henri Termeer for the board of directors.